Type your tag names separated by a space and hit enter

Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies.


Alpha-1-antitrypsin deficiency (AATD) is one of the most frequent genetic causes of liver and lung diseases. Despite its known association with chronic obstructive pulmonary disease (COPD), AATD is largely unrecognised and underdiagnosed. Cases of AATD exist within every COPD or spirometry population but must be actively investigated. AATD is a laboratory diagnosis that must be confirmed by a blood test. A number of clinical 'clues' can raise suspicion of AATD, potentially facilitating earlier diagnosis and initiation of appropriate treatment. Alpha-1-antitrypsin augmentation therapy has a clear role in patients with severe AATD and a FEV1 ≤65% predicted. Emerging evidence suggests that attenuating the decline in lung density may prolong the time to respiratory failure.


  • Publisher Full Text
  • Authors+Show Affiliations

    a Department of Medicine , Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg , Marburg , Germany.


    COPD 14:sup1 2017 Mar 15 pg S8-S11

    Pub Type(s)

    Journal Article



    PubMed ID


    Unbound Prime app for iOS iPhone iPadAlso Available:
    Unbound MEDLINE
    Unbound PubMed app for AndroidUnbound PubMed app for WindowsUnbound PubMed app for MAC OSX Yosemite Macbook Air pro